Quantitative assessment of interaction of urokinase-type plasminogen activator and its receptor (CD87) by use of a solid-phase uPA-ligand binding assay

Fibrinolysis and Proteolysis

Volumn 11, Issue 1, 1997, Pages 11-19

  Goretzki, L ^a   Bognacki, J ^a   Koppitz, M ^a   Rettenberger, P ^b   Magdolen, V ^b   Creutzburg, S ^c   Hammelburger, J ^c   Weidle, U H ^d   Wilhelm, O ^d   Kessler, H ^d   Graeff, H ^c   Schmitt, M ^c  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b Formerly   (United States)

^c TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^d F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CD87 ANTIGEN; UNCLASSIFIED DRUG; UROKINASE; UROKINASE RECEPTOR;

ARTICLE; CONTROLLED STUDY; FIBRINOLYSIS; HUMAN; PRIORITY JOURNAL; QUANTITATIVE ASSAY; RECEPTOR BINDING;

EID: 0031001698     PISSN: 13690191     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0268-9499(97)80004-5     Document Type: Article

References (39)

1. Danø K, Andreasen P A, Grendahl-Hansen J, Kristensen P, Nielsen L S, Skriver L. Plasminogen activators tissue degradation and cancer. Adv Cancer Res 1985; 44: 139-266.
2. Mignatti P, Robbins E, Rifkin D B. Tumor invasion through the human amniotic membrane: requirement for a proteinase cascade. Cell 1986; 47: 487-498.
3. Behrendt N, Rönne E, Danø K. The structure and function of the urokinase receptor: a membrane protein governing plasminogen activation on the cell surface. Biol Chem HoppeSeyler 1995; 376: 269-279.
4. Stopelli M P, Corti A, Soffientini A, Cassani F, Blasi F, Assoian R K. Differentiation enhanced binding of the ammo-terminal fragment of human urokinase plasminogen activator to a specific receptor on U937 monocytes. Proc Nad Acad Sei USA 1985;82:4939-4943.
5. Plow E F, Freaney D E, Plescia T, Miles L A. The plasminogen system and cell surfaces: evidence for plasminogen and urokinase receptors on the same cell type. J Cell Biol 1986; 103: 2411-2420.
6. Nielsen L S, Kellermann G M, Behrendt N, Picone R, Dan0 K, Blasi F. A 55000-60000 Mr receptor protein for urokinase-type plasminogen activator: identification in human tumor cell lines and partial purification. J Biol Chem 1988; 263; 2358-2363.
7. Cubellis M V, Andreasen P, Ragno P, Mayer M, Danø K, Blasi F. Accessibility of receptor-bound urokinase to type-1 plasminogen activator inhibitor. Proc Natl Acad Sei USA 1989; 86: 4828-4832.
8. Conese M, Blasi F. Urokinase/urokinase receptor system: Internalization/degradation of urokinase-serpin complexes: Mechanism and regulation. Biol Chem Hoppe-Seyler 1995; 376: 143-155.
9. Olson D, Pöllänen J, Høyer-Hansen G, Rønne E, Sakaguchi K, Wun T C, Apella E, Danø K, Blasi F. Internalization of the urokinase:plasminogen activator inhibitor type-1 complex is mediated by the urokinase receptor. J Biol Chem 1992; 267: 9129-9133.
10. Cohen RL, Xi X-P, Crowley C W, Lucas B K, Levinson A D, Shuman M A. Effects of urokinase receptor occupancy on plasmin generation and proteolysis of basement membrane by human tumor cells. Blood 1991: 78: 479-487.
11. Crowley C W, Cohen R L, Lucas B K, Liu G, Shuman M A, Levinson A D. Prevention of metastasis by inhibition of the urokinase receptor. Proc Natl Acad Sei USA 1993; 90: 5021-5025.
12. Wilhelm O, Reuning U, Schmitt M, Jänicke F, Graeff H. The role of proteases in tumor invasion and metastasis: Prognostic impact and therapeutical challenge? Onkologie 1994; 17: 358-366.
13. Appella E, Robinson E A, Ullrich S J, Stoppelli M P, Corti A, Cassani G, Blasi F. The receptor binding sequence of urokinase. J Biol Chem 1987; 262: 4437-4440.
14. Chucholowski N, Schmitt M, Rettenberger P, Schüren E, Moniwa N, Goretzki L, Wilhelm O, Weidle U, Jänicke F, Graeff H. Flow cytofluorometric analysis of the urokinase receptor (uPAR) on tumor cells by fluorescent uPA-ligand or monoclonal antibody #3936. Fibrinolysis 1992; 6 Suppl 4: 95-102.
15. Magdolen V, Rettenberger P, Lopens A, Oi H, Lottspeich F, Kellermann J, Creutzburg S, Goretzki L, Weidle U H, Wilhelm O, Schmitt M, Graeff H. Expression of the human urokinase-type plasminogen activator receptor in E. coli and Chinese hamster ovary cells: Purifiction of the recombinant proteins and generation of polyclonal antibodies in chicken. Electrophoresis 1994; 16:813-816.
16. Jänicke F, Schmitt M, Hafter R, Hollrieder A, Babic R, Ulm K, Gössner W, Graeff H. The urokinase-type plasminogen activator (uPA) is a potent predictor for early relapse in breast cancer. Fibrinolysis 1990; 4: 69-78.
17. Kühn W, Fache L, Schmalfeldt B, Dettmar P, Schmitt M, Jänicke F, Graeff H. Urokinase (uPA) and PA1-1 predict survival in advanced ovarian cancer patients (FIGO III) after radical surgery and platinum-based chemotherapy. Gyn Oncol 1994; 55: 401-409.
18. Kolben M, Lopens A, Schmitt M, Schneider K T M, Graeff H. Veränderungen Fibrinolyse-assoziierter. Parameter bei HELLPSyndrom. Geburtshilfe und Frauenheilkunde 1994; 54: 257-261.
19. Möbus V J, Gerharz C D, Press U, Beck T, Meilin W, Follow K, Knapstein P G, Kreienberg R. Morphological immunohistochemical and biochemical characterization of 6 newly established human ovarian carcinoma cell lines. Int J Cancer 1992; 52: 76-84.
20. Will C, Wilhelm O, Höhl S, Möbus V, Weidle U, Kreienberg R, Jänicke F, Schmitt M, Graeff H. Expression of urokinase-type plasminogen activator (uPA) and its receptor (uPAR) in human ovarian cancer cells and in vitro invasion capacity. Int J Oncol 1994; 5: 753-761.
21. Kunkel T A. Rapid and efficient site-specific mutagenesis without phenotypic selection. Proc Natl Acad Sei USA 1985; 82: 488-492.
22. Merrifield R B. Solid phase synthesis. Biosci Rep 1985; 5: 353-376.
23. Barlos K, Chatzi O, Gatos D, Stavropoulos G. 2-Chlorotrityl chloride resin. Studies on anchoring of Fmoc-amino acids and peptide cleavage. Int J Pept Protein Res 1991; 37: 513-520.
24. Schmitt M, Chucholowski N, Goretzki L, Busch E, Hellmann D, Wagner B, Jänicke F, Graeff H. Fluorescent probes as tools to assess the receptor for the urokinase-type plasminogen activator (uPA) on tumour cells. Sem Thromb Haemost 1991; 17: 291-302.
25. Behrendt N, Ploug M, Patthy L, Houen G, Blasi F, Danø K. The ligand binding domain of the cell surface receptor for urokinase-type plasminogen activator. J Biol Chem 1991 ; 266: 7842-7847.
26. Pedersen N, Schmitt M, Ronne E, Nicoletti M I, Hoyer-Hansen G, Conese M, Giavazzi R, Danø K, Kühn W, Jänicke F, Blasi F. A ligand-free soluble urokinase-receptor is present in the ascitic fluid from patients with ovarian cancer. J Clin Invest 1993; 92: 2160-2167.
27. Magdolen V, Rettenberger P, Koppitz M, Goretzki L, Kassier H, Weidle U H, König B, Graeff H, Schmitt M, Wilhem O. Systematic mutational analysis of the receptor-binding region of the human urokinase-type plasminogen activator. Eur J Biochem 1996; 237: 743-751.
28. Kobayashi H, Schmitt M, Goretzki L, Chucholowski N, Calvete J, Kramer M, Günzler W A, Jänicke F, Graeff H. Cathepsin B efficiently activates the soluble and the tumor cell receptorbound form of the proenzyme urokinase-type plasminogen activator (pro-uPA). J. Biol Chem 1991; 266: 5147-5152.
29. Weidle U H, Wollisch E, Rönne E, Ploug M, Behrendt N, Devries T J, Quax P H, Verheijen J H, van Muijen G N P, Ruiter D J, Hoyer-Hansen G, Danø K. Studies on functional and structural role of urokinase receptor and other components of the plasminogen activation system in malignancy. Annales de Biologie Clinique 1994; 52: 775-782.
30. Wilhelm O, Weidle U, Höhl S, Rettenberger P, Schmitt M, Graeff H. Recombinant soluble urokinase receptor as a scavenger for urokinase-type plasminogen activator (uPA): Inhibition of proliferation and invasion of human ovarian cancer cells. FEES Letters 1994; 337: 131-134.
31. Schmitt M, Wilhelm O, Jänicke F, Magdolen V, Reuning U, Ohi H, Moniwa N, Kobayashi H, Weidle U, Graeff H. Urokinase-type plasminogen activator (uPA) and its receptor (CD87). A new target in tumor invasion and metastasis. J Obst Gynaecol 1995; 21: 151-156.
32. Ossowski L, Clunie G, Masucci M T, Blasi F. In vivo paracrine interaction between urokinase and its receptor: Effect on tumour cell invasion. J Cell Biol 1991; 115:1107-1112.
33. Schmitt M, Jänicke F, Graeff H. Tumor-associated proteases. Fibrinolysis 1992; 6 (Suppl.) 4: 3-26.
34. Wilhelm O, Schmitt M, Höhl S, Senekowitsch R, Graeff H. Antisense inhibition of urokinase reduces spread of human ovarian cancer in mice. Clin Exp Metastasis 1995; 13: 296-302.
35. Quattrone A, Fibbi G, Anichini E, Pucci M, Zamperini A, Capaccioli S, del Rosso M. Antimessenger oligonucleotide for urokinase receptor gene inhibits invasivity of transformed human fibroblasts. Anticancer Drug Des 1995; 10: 97-102.
36. Kobayashi H, Ohi H, Shinohara H, Sugimura M, Fujii T, Terao T, Schmitt M, Goretzki L, Chucholowski N, Jänicke F, Graeff H. Saturation of tumor cell surface receptors for urokinase-type plasminogen activator by amino-terminal fragment and subsequent effect on reconstituted basement membranes invasion. Br J Cancer 1993; 67: 537-544.
37. Goodson RJ, Doyle M V, Kaufman S E, Rosenberg S. Highaffinity urokinase receptor antagonists identified with bacteriophage peptide display. Proc Natl Acad Sei USA 1994; 91 : 7129-7133.
38. Wang C I, Yang Q, Craik C S. Isolation of a high affinity inhibitor of urokinase-type plasminogen activator by phage display of ecotin.J Biol Chem 1995; 270: 12250-12256.
39. Jänicke F, Pache L, Schmitt M, Ulm K, Thomssen C, Prechtl A, Graeff H. Both the cytosols and detergent extracts of breast cancer tissues are suited to evaluate the prognostic impact of the urokinase-type plasminogen activator (uPA) and its inhibitor PAI-1. Cancer Res 1994; 54: 2527-2530.